Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$46.85−0.77 (-1.62%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Enliven Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Enliven Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$124.25M. For fiscal 2025 it was -$119.36M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$119.36M | – |
| FY2024 | Dec 31, 2024 | -$104.25M | – |
| FY2023 | Dec 31, 2023 | -$83.23M | – |
| FY2022 | Dec 31, 2022 | -$38.59M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$37.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.81M | – |
| Q4 FY2025 | Dec 31, 2025 | -$34.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$26.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.35M | -153.9% |
| Q4 FY2022 | Dec 31, 2022 | -$10.11M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.96M | – |
| Q1 FY2022 | Mar 31, 2022 | $30.32M | – |
See a number that looks wrong?